Urinary Bladder Neurogenic Dysfunction Clinical Trial
Verified date | December 2016 |
Source | Balgrist University Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | Switzerland: Ethikkommission |
Study type | Observational |
Most patients with spinal cord injury suffer from bladder dysfunction which may - especially in the long-term - impair renal function. Improved treatment during the last decades improved life expectancy and quality of life. This study evaluates the bladder function in the long-term after spinal cord injury.
Status | Completed |
Enrollment | 55 |
Est. completion date | September 2010 |
Est. primary completion date | September 2010 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 90 Years |
Eligibility |
Inclusion Criteria: - Spinal cord injury for at least 5 years - Neurogenic lower urinary tract dysfunction - Written informed consent Exclusion Criteria: - Lower urinary tract dysfunction due to other causes than spinal cord injury |
Observational Model: Case-Only, Time Perspective: Retrospective
Country | Name | City | State |
---|---|---|---|
Switzerland | Spinal Cord Injury Center & Research, University of Zürich, Balgrist University Hospital | Zürich |
Lead Sponsor | Collaborator |
---|---|
Balgrist University Hospital |
Switzerland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Urodynamic evaluation | Max. cystometric capacity, compliance, detrusor leak point pressure | 5 years after SCI, yearly thereafter (participants are followed until death) | No |
Secondary | secondary complications | recurrent tract infection, deterioration of the upper urinary tract | 5 years after SCI, yearly thereafter (participants are followed until death) | No |
Secondary | imaging of the upper urinary tract | videocystography, ultrasound | 5 years after SCI, yearly thereafter (participants are followed until death) | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01530620 -
Efficacy and Tolerability of Propiverine Hydrochloride in Patients With Neurogenic Detrusor Overactivity
|
Phase 3 |